PKC Inhibition in uveal melanoma (UM)
IDEAYA is studying darovasertib, as a single agent and in combination, to potentially improve outcomes and survival across all stages of UM.
Unlocking a core driver of uveal melanoma by targeting PKC—a sustained tumor dependency present in more than 90% of cases13
In uveal melanoma, GNAQ/11 mutations drive a signaling cascade that locks cells into constant growth through persistent activation of protein kinase C (PKC).14 Because PKC sits at the center of this pathway, it remains a key vulnerability across all patients as the disease progresses and metastasizes.13
Darovasertib was designed to inhibit PKC and address the primary driver of UM at every disease stage. It has the potential to serve as a selective monotherapy for local disease or be combined with a cMET inhibitor when the disease metastasizes. This approach is designed to arrest disease progression and improve survival.
A multi-pronged approach across the disease continuum
By blocking core PKC-driven signaling, IDEAYA is deploying a strategy that may target the primary driver of the disease itself.
Discover IDEAYA
PKC = Protein Kinase C, HGF = hepatocyte growth factor, UM = uveal melanoma, mUM = metastatic UM, FDA = Food and Drug Administration